Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mouse models of nonalcoholic steatohepatitis in preclinical drug development
Henrik H. Hansen, Michael Feigh, Sanne Skovgård Veidal, et al.
Drug Discovery Today (2017) Vol. 22, Iss. 11, pp. 1707-1718
Open Access | Times Cited: 218

Showing 1-25 of 218 citing articles:

Immune cell-mediated features of non-alcoholic steatohepatitis
Thierry Huby, Emmanuel L. Gautier
Nature reviews. Immunology (2021) Vol. 22, Iss. 7, pp. 429-443
Open Access | Times Cited: 391
Animal Models of Nonalcoholic Fatty Liver Disease—A Starter’s Guide
Mikhaïl Van Herck, Luisa Vonghia, Sven Francque
Nutrients (2017) Vol. 9, Iss. 10, pp. 1072-1072
Open Access | Times Cited: 349
Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis
Geoff Farrell, Jörn M. Schattenberg, Isabelle Leclercq, et al.
Hepatology (2018) Vol. 69, Iss. 5, pp. 2241-2257
Open Access | Times Cited: 277
The ménage à trois of autophagy, lipid droplets and liver disease
Yasmina Filali-Mouncef, Catherine J. Hunter, Federica Roccio, et al.
Autophagy (2021) Vol. 18, Iss. 1, pp. 50-72
Open Access | Times Cited: 229
Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?
Mark A. Febbraio, Saskia Reibe, Shabnam Shalapour, et al.
Cell Metabolism (2018) Vol. 29, Iss. 1, pp. 18-26
Open Access | Times Cited: 222
Animal models for liver disease – A practical approach for translational research
Yulia A. Nevzorova, Zoé Boyer-Díaz, Francisco Javier Cubero, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 2, pp. 423-440
Open Access | Times Cited: 194
Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis
Michelle L. Boland, Rhianna C. Laker, Karly M. Mather, et al.
Nature Metabolism (2020) Vol. 2, Iss. 5, pp. 413-431
Open Access | Times Cited: 194
Animal models of NAFLD from a hepatologist's point of view
Daniel Jahn, Stefan Kircher, Heike M. Hermanns, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2018) Vol. 1865, Iss. 5, pp. 943-953
Open Access | Times Cited: 172
Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma
Yeming Yang, Jingshu Cai, Xue Yang, et al.
Molecular Therapy (2022) Vol. 30, Iss. 6, pp. 2342-2353
Open Access | Times Cited: 118
Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis
K.S. Tølbøl, Maria Nicoline Baandrup Kristiansen, Henrik H. Hansen, et al.
World Journal of Gastroenterology (2018) Vol. 24, Iss. 2, pp. 179-194
Open Access | Times Cited: 116
Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source
Michelle L. Boland, Denise Oró, K.S. Tølbøl, et al.
World Journal of Gastroenterology (2019) Vol. 25, Iss. 33, pp. 4904-4920
Open Access | Times Cited: 104
In Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal
Pierre‐Antoine Soret, Julie Magusto, Chantal Housset, et al.
Journal of Clinical Medicine (2020) Vol. 10, Iss. 1, pp. 36-36
Open Access | Times Cited: 97
Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis
Henrik H. Hansen, Helene M. Ægidius, Denise Oró, et al.
BMC Gastroenterology (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 96
Modeling the Western Diet for Preclinical Investigations
Korry Hintze, Abby D. Benninghoff, Clara E. Cho, et al.
Advances in Nutrition (2018) Vol. 9, Iss. 3, pp. 263-271
Open Access | Times Cited: 92
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
F. Anthony Romero, Christopher T. Jones, Ying‐zi Xu, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 10, pp. 5031-5073
Closed Access | Times Cited: 81
Naringenin alleviates nonalcoholic steatohepatitis in middle-aged Apoe−/−mice: role of SIRT1
Yi Qiao Hua, Yi Zeng, Jin Xu, et al.
Phytomedicine (2020) Vol. 81, pp. 153412-153412
Closed Access | Times Cited: 81
Deep learning enables pathologist-like scoring of NASH models
Fabian Heinemann, Gerald Birk, Birgit Stierstorfer
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 79
New drugs for NAFLD: lessons from basic models to the clinic
Katharina C. Reimer, Alexander Wree, Christoph Roderburg, et al.
Hepatology International (2019) Vol. 14, Iss. 1, pp. 8-23
Closed Access | Times Cited: 79
Activation of thyroid hormone receptor‐β improved disease activity and metabolism independent of body weight in a mouse model of non‐alcoholic steatohepatitis and fibrosis
Aimo Kannt, Paulus Wohlfart, Andreas Nygaard Madsen, et al.
British Journal of Pharmacology (2021) Vol. 178, Iss. 12, pp. 2412-2423
Open Access | Times Cited: 78
Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH
Marica Cariello, Elena Piccinin, Antonio Moschetta
Cellular and Molecular Gastroenterology and Hepatology (2021) Vol. 11, Iss. 5, pp. 1519-1539
Open Access | Times Cited: 77
Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet‐induced obese and biopsy‐confirmed mouse model of NASH
Mathias B. Møllerhøj, Sanne Skovgård Veidal, Kirstine Tølbøl Thrane, et al.
Clinical and Translational Science (2022) Vol. 15, Iss. 5, pp. 1167-1186
Open Access | Times Cited: 46
Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies
Tingyu Fang, Hua Wang, Xiaoyue Pan, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 15, pp. 5681-5697
Open Access | Times Cited: 42
Lactobacillus sakei MJM60958 as a Potential Probiotic Alleviated Non-Alcoholic Fatty Liver Disease in Mice Fed a High-Fat Diet by Modulating Lipid Metabolism, Inflammation, and Gut Microbiota
Huong Thi Nguyen, Mingkun Gu, Pia Werlinger, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13436-13436
Open Access | Times Cited: 41
An update on animal models of liver fibrosis
ShuTing Wu, Xinxin Wang, WenBo Xing, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 32
Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets
Yinshuang Chen, Weipeng Wang, Maria P. Morgan, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 31
Page 1 - Next Page

Scroll to top